← USPTO Patent Grants

Targeted T-cell therapy for treatment of multiple myeloma

Grant US12590292B2 Kind: B2 Mar 31, 2026

Assignee

Children's National Medical Center

Inventors

Catherine Mary Bollard, Conrad Russell Y. Cruz, Patrick Hanley

Abstract

Provided herein are activated adoptive T-cell compositions targeting plasma cell dyscrasias such as multiple myeloma and methods of treating plasma cell dyscrasias such as multiple myeloma using such compositions. The T-cell compositions of the present disclosure are activated against a select group of antigens associated with multiple myeloma (MMAAs) and, in certain embodiments, in combination with more widely expressed tumor associated antigens (TAAs). In particular, the T-cell compositions of the present disclosure are directed to the MMAAs selected from B-cell maturation antigen (BCMA), X box Protein 1 (XBP1), CS1, and Syndecan-1 (CD138), or a combination thereof. In certain embodiments, the T-cell composition includes T-cells activated to a TAA selected from preferentially expressed antigen of melanoma (PRAME), Survivin, Wilms' Tumor 1 protein (WT1), and melanoma antigen 3 (MAGE-A3), or a combination thereof.

CPC Classifications

C12N 5/0638 A61K 40/11 A61K 40/4215 A61K 40/4224 A61K 40/424 A61K 40/4242 A61K 40/4243 A61K 40/427 A61P 35/00 A61P 35/02 A23B 11/1332 H10D 30/6891 H10D 30/798 H10D 62/161 H10D 80/251 H10F 30/223 H10F 39/15

Filing Date

2020-01-07

Application No.

17421287

Claims

10

View original document →